Amorphous form of apremilast
US-9351957-B2 · May 31, 2016 · US
Forms of apremilast
US10196355B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10196355-B2 |
| Application number | US-201615186687-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 20, 2016 |
| Priority date | Jun 20, 2016 |
| Publication date | Feb 5, 2019 |
| Grant date | Feb 5, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.
First claim
Opening claim text (preview).
What is claimed is: 1. Apremilast Form H, wherein: Form H is characterized by having 2 or more X-ray powder diffraction peaks selected from about 14.02, 19.41, 20.81 and 29.01 °2θ. 2. Apremilast Form H, according to claim 1 , wherein: Form H has an X-ray powder diffraction pattern substantially as shown in FIG. 1 . 3. Apremilast Form H, wherein: Form H is characterized by having 2 or more X-ray powder diffraction peaks selected from about 6.311, 4.570, 4.266 and 3.076 Angstroms. 4. Apremilast Form H according to claim 1 , wherein, as measured by differential scanning calorimetry: Form H is characterized by an endothermic event at about 113° C. 5. Apremilast Form H according to claim 1 , wherein: Form H is characterized by a differential scanning calorimetry pattern substantially as shown in FIG. 7 . 6. A composition comprising apremilast Form H according to claim 1 . 7. The composition according to claim 6 , wherein the composition is a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient. 8. A method of treating psoriatic arthritis and psoriasis comprising administering a pharmaceutical formulation according to claim 7 to a subject in need thereof. 9. A method of making apremilast Form H according to claim 1 , comprising exposing a starting material comprising apremilast to dimethylformamide and water to yield apremilast Form H. 10. A method of making apremilast Form H according to claim 1 , comprising exposing a starting material comprising apremilast to dimethylformamide and tert-butyl methyl ether to yield apremilast Form H.
Assignees
Inventors
Classifications
- C07D209/48Primary
with oxygen atoms in positions 1 and 3, e.g. phthalimide · CPC title
Crystalline forms, e.g. polymorphs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10196355B2 cover?
- The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.
- Who is the assignee on this patent?
- Johnson Matthey Plc
- What technology area does this patent fall under?
- Primary CPC classification C07D209/48. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).